ArticleFrontiers in immunology2026
Definitive chemoradiotherapy plus immune checkpoint inhibitors for locally advanced unresectable esophageal squamous cell carcinoma: survival and progression patterns in a propensity-matched cohort.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Locally advanced unresectable esophageal squamous cell carcinoma (ESCC) remains a therapeutic challenge, with limited survival outcomes following definitive chemoradiotherapy (CRT). Recent evidence suggests that combining immune checkpoint inhibitors (ICIs) with CRT may enhance therapeutic response. Nevertheless, its efficacy, progression behavior, and prognostic indicators require further elucidation. Methods: A retrospective review was performed on ESCC patients treated at Fujian Cancer Hospital from August 2019 to August 2024. 67 patients receiving definitive CRT combined with ICIs (CRT+ICIs) were compared with 415 historical controls treated with CRT alone. To correct for baseline imbalances, 1:3 propensity score matching (PSM) was applied. The Kaplan-Meier method was employed to assess survival outcomes, while progression patterns were evaluated via Fine-Gray competing risks model. Cox proportional hazards analyses were used to determine prognostic factors for overall survival (OS). Results: After PSM, 62 individuals were retained in the CRT+ICIs group and the matched CRT group included 149. The CRT+ICIs exhibited a significantly prolonged median OS (31.1 vs. 18.6 months, p = 0.013) and showed a tendency toward longer PFS (18.6 vs. 12.1 months, p = 0.176). Fine-Gray analysis indicated a nonsignificant 34% reduction in distant progression for CRT+ICIs group (p = 0.160), while local-regional progression risk was declined over time. In the CRT+ICIs group, multivariable analysis identified M stage, lactate dehydrogenase-to-albumin ratio (LAR) and prognostic nutritional index (PNI) as independent prognostic factors for OS. Among these patients, 38.7% experienced grade 3 or higher adverse events with manageable immune-related toxicity. Conclusions: CRT combined with immunotherapy significantly prolongs OS and may delay early distant progression in locally advanced unresectable ESCC, with manageable toxicity. These findings warrant prospective validation and support biomarker-driven patient selection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.